Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panitumumab first-line CRC trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen/Abgenix initiate a Phase III trial of the epidermal growth factor receptor antagonist panitumumab in first-line metastatic colorectal cancer, the firms announce April 26. The open-label PACCE (Panitumumab Advanced Colorectal Cancer Evaluation) trial will randomize 1,000 patients to receive panitumumab on top of either an oxaliplatin- (Sanofi-Aventis' Eloxatin) or irinotecan-based (Pfizer's Camptosar) regimen. Amgen is also preparing to submit an application in the second half of 2005 for panitumumab's use in third-line CRC (1Pharmaceutical Approvals Monthly April 2005, In Brief)...

You may also be interested in...

Amgen preps panitumumab NDA

Amgen plans to submit its epidermal growth factor receptor inhibitor panitumumab in the second half of 2005 for treatment of third-line colorectal cancer, the firm says March 29. Two Phase III trials, one each in the U.S. and EU, are ongoing. "In recent discussions with the FDA, we have obtained favorable opinion regarding the acceptability of these studies for U.S. registration," Senior Director-Licensing Anthony Gringeri, PhD, tells investors at the Smith Barney Citigroup Healthcare conference. Amgen maintains the monoclonal antibody has advantages over Bristol-Myers Squibb/ImClone's EGFR agent Erbitux (cetuximab), including "fewer infusion reactions"...

Flying High: Quest Teams With Las Vegas Walmart To Deliver COVID-19 Tests By Drone

Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.

Executives On The Move: New CEO Appointed At Xwpharma

New directors at 4D Pharma, Neurogene And Zogenix.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts